Dr. Martin Edwards has served on our board of directors since September 2017. Dr. Edwards currently serves on the board of directors of Morphic Holdings, Inc. and Verona Pharma plc, both of which are publicly traded pharmaceutical companies, and previously served on the board of directors of Reata Pharmaceuticals Inc., from July 2020 to September 2023, CoLucid Pharmaceuticals, Inc., from January 2015 to March 2017, and KalVista Pharmaceuticals, Inc., from July 2019 to October 2022.
Dr. Edwards also served as Senior Partner at Novo Holdings A/S from 2003 to 2020. Earlier in his career, Dr. Edwards served as chief executive officer of ReNeuron Ltd., a stem cell research company based in the United Kingdom, and as global head of drug development for Novo Nordisk A/S, where he led preclinical and clinical drug development. Dr. Edwards received an MBA from the University of Warwick (UK) and his medical degree from the University of Manchester (UK).